XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (1,469,000) $ (829,000)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 775,000 572,000
Loss on disposal or impairment of long-lived assets 40,000  
Loss on extinguishment of debt 300,000  
Stock-based compensation expense 907,000 883,000
Amortization of deferred commissions 9,000 10,000
Amortization of debt discount and issuance costs 23,000 23,000
Amortization of right-of-use assets 45,000 81,000
Change in fair value of liabilities 50,000 (12,000)
Provision for accounts receivable 140,000 28,000
Changes in operating assets and liabilities:    
Accounts receivable (558,000) (284,000)
Prepaid expenses and other assets (240,000) (137,000)
Accounts payable and accruals (22,000) 206,000
Operating lease liability (48,000) (112,000)
Deferred revenue 4,000 (226,000)
Net cash provided by (used in) operating activities (44,000) 203,000
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of equipment (3,000) (57,000)
Software development costs (472,000) (490,000)
Patent costs (4,000)  
Payment for acquisition (311,000)  
Net cash used in investing activities (790,000) (547,000)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from term loan, net of lender fees 11,950,000  
Payments for costs directly attributable to the issuance of term loan (325,000)  
Repayment of term loan (7,000,000)  
Payments for debt extinguishment costs (249,000)  
Proceeds from exercise of options 38,000  
Payments related to settlement of employee shared-based awards (966,000) (160,000)
Repurchase of common stock   (1,686,000)
Repayments of finance leases   (6,000)
Net cash provided by (used in) financing activities 3,448,000 (1,852,000)
Net increase (decrease) in cash and cash equivalents 2,614,000 (2,196,000)
Cash and cash equivalents -beginning of period 5,651,000 9,236,000
Cash and cash equivalents - end of period $ 8,265,000 $ 7,040,000